Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysosomal pH modulation refers to the process of altering the acidity within lysosomes, which are membrane-bound organelles responsible for degrading and recycling cellular components via extremely acidic conditions (pH 4.5–5.5)[1][4][5]. Acidification is driven by vacuolar-type H+-ATPase (V-ATPase) proton pumps, supported by counter-ion transporters such as ClC-7 chloride transporters and other ion exchangers[4][7]. Precise regulation is vital for activation of hydrolytic enzymes and proper degradation of cellular waste[3][5]. Disturbances in lysosomal pH homeostasis impair lysosomal function and are implicated in the pathogenesis of numerous diseases, including neurodegenerative disorders, metabolic defects, cancer, inflammatory and infectious diseases[1][5]. Some pharmacological agents, such as bafilomycin A1, chloroquine, and ammonium chloride, target lysosomal acidification by either inhibiting proton pumps or neutralizing protons, while other strategies include nanoparticle-based delivery or ion channel modulation[1][4]. However, "lysosomal pH modulation" is a process or intervention, not a discrete molecular entity, protein, enzyme, transporter, or receptor, and is thus not itself a canonical therapeutic target, but rather a mechanism impacting several molecular targets involved in lysosome acidification.\n\nThere is something incorrect with the target as stated: "Lysosomal pH modulation" is not a specific molecule, receptor, enzyme, or protein, but describes a cellular process or intervention, involving several molecular components such as V-ATPase, ion channels (e.g., ClC-7), and various transporters[1][3][4][7]. For structured databases aiming to describe molecule/receptor targets, the specific components regulating lysosomal pH (such as V-ATPase or ClC-7) should be considered as molecular targets instead.
Inhibition or activation of proton pumps (e.g., V-ATPase inhibitors/activators)\n- Lysosomotropic agents raise pH by accumulating in lysosomes and buffering protons\n- Ion channel or transporter modulators affect accompanying charge balancing for acidification
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysosomal pH modulation.